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Abstract
Epidemiological studies have reported associations between circulating inflammation markers and
risk of chronic diseases. It is of interest to examine whether risk factors for these diseases are
associated with inflammation. We conducted a cross-sectional analysis to evaluate whether
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reproductive and lifestyle factors and circulating vitamin D were associated with inflammation
markers, including C-reactive protein, cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40,
IL-12p70, IL-13, TNFα), and cytokine modulators (IL-1RA, sIL-lRII, sIL-2Ra, sIL-4R, sIL-6R,
sTNF-R1/R2), among 616 healthy women. We confirmed associations of several inflammation
markers with age and BMI. We also observed significantly higher levels of certain inflammation
markers in postmenopausal versus premenopausal women (TNFα, sIL-1RII, sIL-2Ra), with
increasing parity (IL-12p40), and with higher circulating 25(OH) vitamin D (IL-13) and lower
levels among current users of non-steroidal anti-inflammatory drugs (NSAIDs) (IL-1β, IL-2,
IL-10, IL-12p70, and IL-12p40), current smokers (IL-4, IL-13, IL-12p40), and women with a
family history of breast or ovarian cancer (IL-4, IL-10, IL-13). Our findings suggest that risk
factors for chronic diseases (age, BMI, menopausal status, parity, NSAID use, family history of
breast and ovarian cancer, and smoking) are associated with inflammation markers in healthy
women.
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1. Introduction
Several studies have shown that elevated inflammation markers, primarily C-reactive protein
(CRP), interleukin (IL)-6, and tumor necrosis factor (TNFα), are associated with increased
risk of cardiovascular disease, type II diabetes, and other chronic conditions, including
cancer [1–9]. We recently conducted a case-control study of ovarian cancer nested in three
prospective cohorts, and found that IL-2, IL-4, IL-6, IL-12, and IL-13 were associated with
risk [10]. Several inflammation-related markers, including IL-2, IL-5, TNFβ, interferon γ
(IFNγ), ICAM, soluble IL-2 receptor (sIL-2R), and soluble TNFα receptor 1 (sTNF-R1),
have been found to be positively, and IL-13 inversely, associated with subsequent risk of
non-Hodgkin lymphoma (NHL) [11–13]. Given the potential role of inflammation in
chronic disease, it is of interest to identify factors that contribute to differences in levels of
inflammation markers among healthy people.
The emphasis of previous studies has generally been on the association between a limited
number of inflammation markers (usually CRP, IL-6, TNFα) and general lifestyle and/or
cardiovascular risk factors [1, 14,15]. The focus of the present study was to assess whether
reproductive and lifestyle factors and circulating vitamin D, which is immunomodulatory
and has anti-inflammatory properties in vitro [16, 17], are associated with CRP, cytokines
(IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-13, TNFα) and cytokine
modulators/soluble receptors (IL-1 receptor antagonist (Ra), soluble (s)IL-1RII, sIL-2Ra,
sIL-4R, sIL-6R, and sTNF-R1/R2) in healthy women. We selected inflammation markers
that showed adequate temporal reproducibility (ICC ≥ 0.5) over a 2–3 year period in
preliminary reproducibility studies, thus suggesting that a single inflammation marker
measurement can be used to rank women according to their average level [18–20].
2. Materials and Methods
2.1 Study Subjects
For these cross-sectional analyses, we included healthy controls from two nested case-
control studies in which inflammation markers have been measured: 1) a study of ovarian
cancer in three prospective cohorts: the New York University Women’s Health Study
(NYUWHS-OVCA), the Northern Sweden Health and Disease Study (NSHDS), and
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ORDET in Italy [10]; and 2) a study of non-Hodgkin lymphoma in the NYUWHS cohort
(NYUWHS-NHL) [11]. The parent cohorts have been described in detail previously [21–
24]. Controls were selected to match cases on age (± 6 months), date of blood sampling (± 3
months), and parent cohort (NYUWHS, NSHDS, or ORDET). Controls also had to be alive
and free of cancer at the time of the matched case’s cancer diagnosis. Participants were not
eligible for inclusion if they were using hormone replacement therapy (HRT) or oral
contraceptives (OC) at the time of blood sampling. Up to two controls per case were
selected at random from cohort members who met the above criteria. We included all 616
controls from the nested case-control studies in the present cross-sectional analysis (163
controls from NYUWHS-OVCA, 82 from ORDET, 187 from NSHDS, and 184 from
NYUWHS-NHL).
Self-reported questionnaires were used to collect data on lifestyle and reproductive variables
and height and weight for the NYUWHS and NSHDS subjects. ORDET participants
completed in-person interviews with a nurse who also measured height and weight.
Although questionnaires varied according to cohort, harmonization of variables was usually
straightforward. Participants were considered to have a family history of breast or ovarian
cancer only if cancer was reported for a first degree relative (i.e. mother, sister, or daughter).
The NSHDS questionnaire asked about “current use” of NSAIDs whereas the NYUWHS
questionnaire asked about NSAID use over the previous four weeks. To harmonize
NYUWHS and NSHDS data, we restricted NSAID use to use the day of, or one day prior to,
blood sampling for the NYUWHS participants, which is more similar to the data that was
collected from NSHDS participants. This cut-off is also justified because the half-life of
most NSAIDs is less than two days in circulation [25]. ORDET did not collect information
on NSAIDs.
2.2 Laboratory Methods
Luminex multiplex bead-based technology was used for measurement of inflammation
markers in serum (NYUWHS and ORDET) and EDTA plasma (NSHDS) [26]. The assay
kits and procedures and coefficients of variation (CVs) have been described previously in
our reproducibility and case-control studies [10, 11,19, 20].
25(OH)D was measured using a direct, competitive chemiluminescence immunoassay
(DiaSorin LIAISON 25 OH Vitamin D TOTAL Assay) for the NYUWHS-OVCA and
NYUWHS-NHL serum samples. NSHDS plasma 25(OH)D was measured using a gamma-B
25-hydroxy vitamin D radioimmunoassay (Immunodiagnostic Systems, Inc.). Details about
the 25(OH)D measurements have been described previously [27–29].
2.3 Statistical Methods
Cytokine measurements that were below the lower limit of detection (LLD) were imputed.
For eleven markers with less than 5% of the measurements below the lower limit of
detection (LLD), we assigned a value equal to the midpoint between the LLD and zero. For
seven markers with 5% or more values below the LLD (IL-1β, IL-2, IL-4, IL-5, IL-12p70,
IL-13, IL-1RA had 17–25% values below the lower limit of detection), we used a maximum
likelihood estimation procedure developed by Lubin et al. to perform multiple imputation in
the presence of detection limits [30]. For the NHL study, sIL-1RII and sIL-4R were not
measured, sIL-2Ra was measured with a different assay, and sIL-6R measurements were
outside of the detection limits of the assay, thus NHL samples are not included in the
analysis of these four markers. Cytokine values were log-transformed to reduce departures
from the normal distribution.
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We estimated geometric means for each cytokine adjusted for study (NYUWHS-OVCA,
NYUWHS-NHL, NSHDS, ORDET), age (continuous), and BMI (continuous, log2-
transformed) within categories of a number of descriptive variables: age (adjusted for study
and BMI only), BMI (adjusted for study and age only), menopausal status (pre/post),
number of full term pregnancies, smoking status at blood sampling (current/former/never),
first degree family history of breast or ovarian cancer (yes/no), use of NSAIDS at blood
sampling (yes/no), use of vitamin supplements at time of blood sampling (yes/no), and ever
use of OCs (yes/no). Multivariate regression analyses were conducted to assess which
variables were independently associated with each cytokine. Partial Pearson correlations
were estimated between log-transformed cytokines and cytokine modulators, adjusting for
study, age and BMI. Analyses were conducted using SAS version 9.2 (SAS Institute, Cary,
NC). All statistical tests were two-sided and P-values < 0.05 were considered significant.
The Institutional Review Board of New York University School of Medicine, the Ethical
Review Board of the National Cancer Institute of Milan (Italy), the Regional Ethical
Committee of the University of Umeå, Sweden, and the Swedish Data Inspection Board
reviewed and approved this study.
3. Results
Characteristics of the study subjects are shown in Table 1. The age range at blood sampling
was 30–75 years (mean = 55 years), and 66% of the women were post-menopausal. The
median BMI was about 25kg/m2. Thirty-five percent of women had previously used oral
contraceptives, 23% were nulliparous, and 82% of parous women had 2 or more children.
Eighteen percent of women reported having a first-degree family history of breast or ovarian
cancer. At the time of blood sampling, 18% were current smokers, 17% were taking
NSAIDs, and 42% were using multivitamins.
Cytokine Distributions by Subject Characteristics
Age-, BMI-, and study-adjusted geometric means and 95% confidence intervals (CI) for
selected characteristics are shown in Tables 2 and 3 for cytokines and cytokine modulators,
respectively. Table 4 shows beta estimates from multivariate models controlling for all
characteristics significantly associated with each marker.
Age and Menopausal Status—There was a significant increasing trend across age
groups for CRP, IL-6, and TNFα (Table 2) and for sIL-1RII, sIL-2Ra, sIL-6R, sTNF-R1,
and sTNF-R2 (Table 3). After adjusting for menopausal status (Table 4), age was no longer
significantly associated with TNFα, sIL-1RII, and sIL-2Ra; these three markers were
significantly higher in postmenopausal women (Tables 2–4).
BMI—As shown in Tables 2 and 3, age-adjusted inflammation marker levels increased
significantly with increasing BMI for five markers: CRP, TNFα, sIL-1RII, sIL-6R, and
sTNF-R1. Though other cytokines did not show a significant trend with increasing BMI,
levels were highest among obese women (BMI > 35 kg/m2) for several markers.
Parity—IL-12p40 showed a significant increasing trend with parity (Table 3), though this
association was no longer significant after adjustment for smoking (Table 4).
Family History of Breast or Ovarian Cancer—Several markers were significantly
lower in women with a family history of breast or ovarian cancer: IL-4, IL-10, and IL-13
(Table 2). However, the association between family history of breast and ovarian cancer was
no longer significant for IL-4 or IL-13 after controlling for smoking (Table 4).
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Current use of NSAIDs—Current users of NSAIDs had significantly lower levels of
IL-1β, IL-2, IL-10, IL-12p70, and IL-12p40 (Tables 2 and 3). However, NSAID use was no
longer associated with IL-12p40 after controlling for smoking (Table 4).
Smoking Status—Current smokers had significantly lower levels of IL-4, IL-13, and
IL-12p40 (Tables 2–4). Former smokers had significantly lower levels of IL-4 and IL-10
(Table 2) and higher levels of sTNF-R2 (Table 3). However, IL-10 was not associated with
smoking in multivariate models, while IL-6 was lower among former smokers in the
multivariate model adjusted for age (Table 4).
Vitamin D (25(OH)D)—Women with 25(OH)D levels above 50 nmol/L had generally
higher levels of inflammatory markers than did women with lower 25(OH)D levels, but the
difference was only statistically significant for IL-13 (Tables 2 and 3), and this difference
was no longer significant after adjustment for smoking (Table 4).
Other Variables—We did not observe any significant differences in cytokine levels
related to ever use of oral contraceptives or current use of multivitamins. Thus, these
characteristics are not shown in Tables 2–4.
Cytokine Correlations
Pearson correlation coefficients adjusted for age, BMI, and study are shown in Table 5. CRP
was weakly correlated with the cytokine IL-6 and the cytokine modulator sIL-2Ra (r~ 0.1–
0.2). Cytokines were significantly correlated with all other cytokines. The strongest
correlations (r > 0.6) were observed between IL-1β and IL-2, IL-10 and IL-12p70, and
among the following markers: IL-4, IL-5, IL-6, and IL-13. Correlations between cytokines
and cytokine modulators were weak for most pairs (r <0.4), though moderate correlations
(r~0.5) were observed between IL-12p40 and two modulators: IL-1RAandsTNF-R1.
4. Discussion
Our results support three previous studies that observed higher levels of the pro-
inflammatory cytokine TNFα among post-menopausal women [31–33], although others did
not observe such a difference [34, 35], or observed lower levels [36]. Two soluble cytokine
receptors, sIL-1RII and sIL-2Ra were also higher among post- vs. pre-menopausal women.
The associations were apparent after adjustment for age and BMI, which suggests that these
markers may be influenced by sex hormones.
Increasing parity was associated with higher levels IL-12p40, although this association was
no longer statistically significant after adjustment for smoking. We are unaware of previous
reports that have evaluated the association between previous pregnancies and inflammation
markers. However, a microarray study of normal breast tissue found that several
inflammation-associated genes were upregulated in both recently (0–2 years since
pregnancy) and distantly (5–10 years since pregnancy) parous vs. nulliparous women [37].
However, despite adjustment for age and BMI, we cannot exclude the possibility that the
association may have been confounded by other factors, including age at each pregnancy
and time since last pregnancy.
Women with a first degree family history of breast or ovarian cancer had lower levels of
several cytokines. While inflammation marker levels are not likely to be directly related to
family history, this risk factor may be associated with adoption of healthy lifestyle elements.
Current use of NSAIDs was inversely associated with a number of inflammatory markers
(IL-1β, IL-2, IL-10 and IL-12p70), in line with our expectations. However, NSAID use was
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not associated with levels of CRP. Prior reports on the association between NSAID use and
CRP are conflicting [38–43], which may be due to differences in duration, types, and doses
of NSAID evaluated, but also because some studies were limited in sample size [38–40, 42],
included subjects with existing chronic disease [43], or reported associations for regular
users who were asked to abstain from use prior to blood sampling [41].
Somewhat contrary to our expectations, smoking status was not significantly associated with
CRP, IL-6, TNFα or other pro-inflammatory cytokines. In our study, current smokers
generally had lower levels of cytokines than non-smokers, though these associations were
only statistically significant for the anti-inflammatory markers, IL-4, IL-13 and IL-12p40.
Lower levels of these cytokines among smokers vs. non-smokers were observed in all four
sub-studies (NYUWHS-OVCA, NYUWHS-NHL, ORDET, and NSHDS). Previous studies
on current smoking and cytokines among healthy individuals have found positive [34, 44–
50], inverse [51, 52], and null [49, 52–55] associations. Inconsistent findings may be a result
of incomplete control for lifetime exposure to cigarette smoke (e.g. pack-years), which may
be a more relevant measure of exposure than current smoking status.
CRP was not correlated with most cytokines. Given the role of IL-6, and to a lesser extent
TNFα and IL-1β, in the induction of CRP, we expected to observe moderate to strong
correlations of CRP with these cytokines. In models adjusted for study and age (but not
BMI), CRP was positively correlated with TNFα (r = 0.1, P < 0.005) and IL-6 (r= 0.1,
P=0.001), but not IL-1β. Others have found a moderate correlation between CRP and IL-6,
some of which adjusted for BMI, with most estimating a correlation coefficient between
0.3–0.5 [2, 14, 34, 41, 50, 56, 57]. However, data from the Women’s Health Initiative trial
suggests that there could be IL-6-independent pathways for regulating CRP, as CRP and
IL-6 had different associations with several cardiovascular risk factors: HRT use, alcohol
use, and exercise [44]. For example, the consistent association between CRP and HRT [58]
vs. the weak or null association between IL-6 and HRT, may be due to direct (IL-6-
independent) hepatic induction of CRP [44].
The observed significant correlation between TNFα, IL-6, and IL-1β was expected due to
the regulatory inter-relationship of these cytokines [34, 41, 56, 59, 60]. Cytokines were
correlated with each of the other cytokines, and less so with cytokine modulators. In
physiological conditions, elevations in pro-inflammatory cytokines trigger elevations in anti-
inflammatory cytokines to resolve the inflammatory response. Thus, we expected all pro-
and anti-inflammatory cytokines to be positively correlated with each other in healthy
women. However, since all the cytokines were measured using the same assay kit, we
cannot rule out the possibility that imperfect antibody specificity could have contributed to
the strength of the correlations. The relationship between cytokines and their modulators is
complex, because soluble cytokine receptors can act as both cytokine agonists and/or
antagonists [61]. Possible reasons for the lack of correlation between cytokines and their
modulators have been suggested by others, such as the longer half-life of soluble receptors
in circulation and/or the inability to detect all unbound and bound forms of cytokines with
immunoassays [62–64].
The lack of association between cytokines and 25(OH)D, the best representation of an
individual’s vitamin D status, is in agreement with a study of vitamin D supplementation in
overweight and obese individuals that did not find an association between circulating
25(OH)D and CRP or cytokines (including IL-2, IL-4, IL-5, IL-10, IL-12, IL-13) [52]. We
found some evidence of a positive association for IL-13 and 25(OH)D, though the
association was not significant in multivariate analyses. Others have reported a lack of
association between 25(OH)D and several inflammation markers (CRP, IL-1β, IL-6, IL-10,
SIL-2R, TNFα, sTNF-R1, and sTNF-R2) [65–70], though one small study found an inverse
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association between 25(OH)D and TNFα [65] and two others found that vitamin D
supplementation stabilized [71] or reduced [72] TNFα among patients with congestive heart
failure or obesity, respectively. We note that the median 25(OH)D level in our study group
(median: 48 nmoI/L, interquartile range: 25, 81 nmoI/L) is considered to be in the
“insufficient” range (~<50 nmoI/L) based on some recommendations [73, 74].
This study has a number of strengths. First, participants were healthy and not using HRT or
OCs for at least 6 months prior to blood sampling, thus minimizing the effects of existing
disease and exogenous hormones on cytokine levels. Second, we evaluated associations
between risk factors and a large number of cytokines and cytokine modulators which have
not been evaluated in previous studies. Third, all inflammation marker measurements were
performed in the same laboratory, which minimizes assay variability and allows individuals
to be ranked relative to others.
Our study also has some limitations. First, questionnaires differed between cohorts.
However, results were usually consistent across cohorts, providing confidence in our
findings. Second, it is possible that measured levels of a single cytokine are not reflective of
their biologically relevant concentration. This may be due to assay limitations in
quantification of absolute levels and/or the presence of circulating cytokine inhibitors,
including soluble receptors and other binding proteins. Finally, the exploratory nature of our
analyses resulted in a substantial number of statistical tests, thus it is likely that some
associations were significant due to chance. However, we did not adjust for multiple
comparisons because our goal was to identify general patterns of association that may
explain risk factor associations and to aid in the selection of potential confounders for future
studies of cytokines and chronic disease risk. The associations observed here should be
evaluated in independent studies.
In conclusion, we observed the expected relationships between inflammation markers and
age and BMI. Higher levels of certain markers were observed among postmenopausal vs.
premenopausal women (TNFα, sIL-1RII, and sIL-2Ra) and with increasing parity
(IL-12p40). Lower levels were observed among current versus non-users of NSAIDs (IL-10,
IL-β, IL-10, IL-12p70, and IL-12p40), women with a family history of breast or ovarian
cancer (IL-4, IL-10, and IL-13), and current versus non-smokers (IL-4, IL-13, and
IL-12p40). These findings suggest that one mechanism underlying the relationship between
reproductive and lifestyle factors and chronic diseases may involve inflammation mediators.
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25(OH)D 25-hydroxyvitamin D
BMI body mass index
CV coefficient of variation
CI confidence interval
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ORDET diet and hormones in the etiology of cancer study
EDTA ethylenediaminetetraacetic acid
HRT hormone replacement therapy
ICAM inter-cellular adhesion molecule
IFN interferon
IL interleukin
IL-1Ra interleukin-1 receptor antagonist
ICC intra-class correlation coefficient
LLD lower limit of detection
MET metabolic equivalent tasks
NYUWHS New York University Women’s Health Study
NHL non-Hodgkin lymphomas
NSAID non-steroidal anti-inflammatory drug
NSHDS Northern Sweden Health and Disease Study
OC oral contraceptives
PBMC peripheral blood mononuclear cell
R- suffix receptor
s -prefix soluble
sIL-1RII soluble IL-1 receptor
sIL-2Ra soluble IL-2 receptor alpha
sIL-4R soluble IL-4 receptor
sIL-6R soluble IL-6 receptor
TNF tumor necrosis factor
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Highlights
• We assessed potential determinants of inflammation markers among 616 healthy
women.
• Observed associations between lifestyle and reproductive factors and
inflammation markers.
• Associations: age, BMI, menopause, parity, NSAIDs, family history of cancer,
smoking.
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Table 1
Descriptive Characteristics of Study Subjects
Characteristic N (%)
 Study
 NYUWHS- OVCA 163 (26.5)
 NYUWHS- NHL 184 (29.9)
 ORDET 82 (13.3)
 NSHDS 187 (30.4)
Age at blood sampling, y
 30–45 123 (20.0)
 46–50 74 (12.0)
 51–55 101 (16.4)
 56–60 144 (23.4)
 61–75 173 (28.1)
 Missing 1
Body Mass Index, kg/m2
 <25 303 (51.4)
 25–29 166 (28.1)
 30–34 89 (15.1)
 ≥35 32 (5.4)
 Missing 26
Menopausal Status at Baseline
 Premenopausal 212 (34.5)
 Postmenopausal 403 (65.5)
 Missing 1
Parity
 Nulliparous 124 (23.1)
 1 74 (13.8)
 2 181 (33.7)
 3 104 (19.4)
 4 or more 54 (10.1)
 Missing 79
Family history of breast/ovarian cancera
 No 413 (82.3)
 Yes 89 (17.7)
 Missing 114
Use of NSAIDs at blood sampling a
 No 446 (83.5)
 Yes 88 (16.5)
 Missing 82
Smoking status at blood sampling
 Never 287 (56.0)
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Characteristic N (%)
 Current 92 (18.0)
 Former 133 (26.0)
 Missing 104
Use of vitamins at blood sampling a
 No 308 (58.0)
 Yes 223 (42.0)
 Missing 85
Past use of oral contraceptives
 Never 344 (64.5)
 Ever 189 (35.5)
 Missing 83
25(OH)D status b
 ≤ 50 nmol/L (“insufficient”) 171 (62.9)
 > 50 nmol/L (“sufficient”) 101 (37.1)
 Missing 344
Note: NSAIDs: non-steroidal anti-inflammatory drugs, 25(OH)D: 25-hydroxy vitamin D
a
High proportion of missing data because this variable was not available from ORDET (n=82) subjects.
b
High proportion of missing data because this variable was not available from ORDET (n=82) subjects and from subjects who were not included in
previous studies on 25(OH)D.
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